Lyra Therapeutics 

Yahoo Finance • 6 days ago

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeu... Full story

Yahoo Finance • 2 months ago

Lyra Therapeutics GAAP EPS of -$5.51, revenue of $0.18M

* Lyra Therapeutics press release [https://seekingalpha.com/pr/20198552-lyra-therapeutics-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 2 months ago

Lyra earnings missed by $5.34, revenue fell short of estimates

Investing.com - Lyra (NASDAQ: LYRA) reported second quarter EPS of $-5.510, $5.34 worse than the analyst estimate of $-0.170. Revenue for the quarter came in at $183K versus the consensus estimate of $242K. Lyra’s stock price closed at $6... Full story

Yahoo Finance • 2 months ago

Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

– Positive ENLIGHTEN 2 Phase 3 results announced in June 2025 propel business activities in manufacturing, regulatory strategy and ENLIGHTEN clinical dataset analysis to advance path forward for LYR-210 for treatment of chronic rhinosinusi... Full story

Yahoo Finance • 3 months ago

Lyra Therapeutics registers shares for resale from warrant exercises

* Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) registers 846,744 shares of common stock for resale by selling securityholders. * Shares are issuable upon exercise of outstanding warrants; company will receive... Full story

Yahoo Finance • 3 months ago

Lyra Therapeutics CFO Cavalier sells $6k in shares

Lyra Therapeutics (NASDAQ:LYRA) Chief Financial Officer Jason Cavalier sold 684 shares of common stock on July 10, 2025, at a price of $8.91, for a total transaction value of $6,094. The sale comes as the stock trades near $8.71, down abou... Full story

Yahoo Finance • 4 months ago

Lyra Therapeutics Raises $5 Mln In Direct Offering, Eyes $9.8 Mln Via Warrant Exercises

(RTTNews) - Lyra Therapeutics Inc. (LYRA) announced Friday a registered direct offering of 423,372 shares of common stock (or pre-funded warrants) priced at-the-market under Nasdaq rules, along with a concurrent private placement of warran... Full story

Yahoo Finance • 4 months ago

Lyra Therapeutics to raise up to $15M via registered direct offering and concurrent private placement, stock falls 22%

Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) announced that it will raise capital [https://seekingalpha.com/pr/20150434-lyra-therapeutics-announces-up-to-approximately-15-million-registered-direct-offering-and] th... Full story

Yahoo Finance • 4 months ago

Lyra Therapeutics raises $5 million in registered direct offering

WATERTOWN, Mass. - Lyra Therapeutics, Inc. (NASDAQ:LYRA), currently trading at $13.38 with a market capitalization of $17.73 million, has secured approximately $5 million through a registered direct offering of common stock and warrants, a... Full story

Yahoo Finance • 4 months ago

Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment o... Full story

Yahoo Finance • 4 months ago

Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data

[Markets up] Maxiphoto * Lyra Therapeutics (NASDAQ:LYRA [https://seekingalpha.com/symbol/LYRA]) is up ~376% in Monday trading after releasing phase 3 data on chronic rhinosinusitis candidate LYR-210. * The asset met its primary endpoi... Full story

Yahoo Finance • 4 months ago

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically signifi... Full story

Yahoo Finance • 5 months ago

Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025

Results from ENLIGHTEN 1 Phase 3 Extension Stage support LYR-210’s favorable safety profile and general consistency with the Primary Study Phase in patients with CRS In the CRS patient subgroup with nasal polyps, analysis showed improveme... Full story

Yahoo Finance • 5 months ago

Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of... Full story

Yahoo Finance • 7 months ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities for LYR-210 in CRS patient cohort with n... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc. (NASDAQ: LYRA) (“Lyra”) on behalf of the company’s investors. Since August 2022, shares of Lyra’s common stock ha... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis (CRS) patients who have had p... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announc... Full story

Yahoo Finance • 2 years ago

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Lyra Therapeutics, Inc.; Urges Lyra Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether L... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinu... Full story